Year-end Sale % OFF 
Abstract
While the SARS-CoV-2 pandemic continues to strike and collect its death toll throughout the globe, as of 31 January 2021, the vaccine candidates worldwide were 292, of which 70 were in clinical testing. Several vaccines have been approved worldwide, and in particular, three have been so far authorized for use in the EU. Vaccination can be, in fact, an efficient way to mitigate the devastating effect of the pandemic and offer protection to some vulnerable strata of the population (i.e., the elderly) and reduce the social and economic burden of the current crisis. Regardless, a question is still open: after vaccination availability for the public, will vaccination campaigns be effective in reaching all the strata and a sufficient number of people in order to guarantee herd immunity? In other words: after we have it, will we be able to use it? Following the trends in vaccine hesitancy in recent years, there is a growing distrust of COVID-19 vaccinations. In addition, the online context and competition between pro- and anti-vaxxers show a trend in which anti-vaccination movements tend to capture the attention of those who are hesitant. Describing this context and analyzing its possible causes, what interventions or strategies could be effective to reduce COVID-19 vaccine hesitancy? Will social media trend analysis be helpful in trying to solve this complex issue? Are there perspectives for an efficient implementation of COVID-19 vaccination coverage as well as for all the other vaccinations?
Highlights
Published: 18 February 2021On 27 January 2020, vaccination campaigns against severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) officially started across Europe
We present a case study for Italy with preliminary data on the volume of social media in relation to relevant public communication about anti-COVID-19 vaccines
All these three vaccines require two doses while a point of difference is represented by storage conditions; the AstraZeneca vaccine does not require low-temperature storage, and this is a key element for logistical considerations when planning a mass vaccination campaign
Summary
On 27 January 2020, vaccination campaigns against severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) officially started across Europe. AstraZeneca vaccine relies on a nonreplicative recombinant chimpanzee adenovirus-based platform All these three vaccines require two doses while a point of difference is represented by storage conditions; the AstraZeneca vaccine does not require low-temperature storage, and this is a key element for logistical considerations when planning a mass vaccination campaign. Both BioNTech-Pfizer and Moderna vaccines showed high efficacy in terms of reduction of symptomatic cases, 95% and 94.1%, respectively [15,16]. Thanks to validated platforms long studied before the pandemic, this process could take place relatively rapidly, potentially following the updated model of seasonal flu vaccines
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
